# Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

> **NCT03409614** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 789 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** REGN2810
- **DRUG:** REGN2810/chemo/ipi
- **OTHER:** Chemotherapy
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03409614
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-06
- **Primary completion:** 2025-02-27
- **Final completion:** 2025-02-27
- **Target enrollment:** 789 (ACTUAL)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03409614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03409614, "Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03409614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*